Panel Discussion: Turning Setbacks into Strategy, what Clinical Trial Failures Teach us About Building Better Oligonucleotide Therapies
- Unpack the reasons behind trial discontinuations: Was it the oligo, delivery system, or something else?
- Discuss how teams rebounded, what pivots, partnerships, or reformulations turned failure into future success